Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 ...Middle East

BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2...

Read More Details
Finally We wish PressBee provided you with enough information of ( Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004 )

Also on site :

• Term Sheet Next: How Facebook’s former chief revenue officer is coaching the next generation of startup founders
• Popular Dunkin’ Menu Item Gets a ‘Glow-Up’ in Limited-Edition Release
• Germany: Life imprisonment sentence for Syrian doctor Alaa Moussa